BioPlanta GmbH is a pharmaceutical company that develops cell therapeutic products from mesenchymal stromal cells for clinical application in humans.

Learn more


Where you can meet us

World Phacilitate Leaders Advanced Therapies Miami 2020
World Stem Cell Summit Miami 2020
22nd of January: The role of Mesenchymal Stromal Cells (MSC) in the cartilage repair process
Authors: André G. Gerth, Constanze Heike Opitz
3rd Annual Cell & Gene Therapy Innovation Leaders Summit 2020 - Berlin
Authors: André G. Gerth, Tomasz Oldak, Jakub Baran, Constanze Heike Opitz
7th of September: CartiCure - An ATMP based on Mesenchymal Stromal Cells for Orthopaedic Treatments and Regenerative Medicine.
Authors: André G. Gerth, Tomasz Oldak, Jakub Baran, Constanze Heike Opitz
Cord Blood Connect 2020 – Miami Beach (virtual)
12th of September: Mesenchymal Stromal Cells for Orthopaedic Treatments and Regenerative Medicine.
Authors: André G. Gerth, Tomasz Oldak, Jakub Baran, Constanze Heike Opitz


The shareholder of BioPlanta GmbH already founded a company of the same name in 1992, which was extraordinarily successful in the field of phytoremediation and development of phytotherapeutics and was merged in 2012 with Europe's second largest listed stem cell bank.

In 2017, Animal Service UG was transformed into BioPlanta GmbH, which is very active in the field of biotechnology/life sciences, particularly in the development of applications for regenerative medicine. As a research-based pharmaceutical company, BioPlanta is engaged in the production and development of biomedical drugs for clinical application in humans, in particular for the treatment of orthopaedic diseases. The focus is on both allogeneic and autologous therapy concepts. The main focus of the company is in the area of contract development and manufacturing of stem cell-based cell preparations.

Research & development at BioPlanta GmbH aims to increase product quality by extending quality assurance measures as well as to expand the application possibilities of stem cell-based products for new indications.

In addition, BioPlanta advises German and international clients on the establishment and strategic development of biotechnology companies, in particular in the field of regenerative medicine.

Management and Key Staff

Dr. André Gerth

  • Founder and Managing Director of BioPlanta GmbH until merger with Vita 34 AG in 2012, re-establishment of BioPlanta GmbH in 2017
  • Chairman of the Management Board of Vita 34 AG 2012 to 2017
  • Management expertise in small and medium-sized biotech companies
  • Many years of experience in the field of corporate development
  • Experience in international B2B business in the markets of Europe, Central and South America and Asia

Dr. Heike Opitz

  • Founder and Project Manager BioPlanta GmbH (until 1997)
  • Project manager in companies, in the field of economic development of the Regional Council of Leipzig and the University of Leipzig
  • 2001 - 2018 Manager Business Development of Vita 34 AG
  • Experience in the management of cooperation projects and R&D projects
  • Expertise in the development and approval of stem cell products and medical devices

Cell therapies

Cell therapy is currently undergoing a paradigm shift from autologous to allogenic therapy concepts.

Autologous Allogenic
Painful, invasive collection No collection morbidity
Higher patient costs
(Removal costs cartilage approx. 2.250 EUR)
Lower patient costs
Lower margins (10%) Higher margins (40%)
4 - 6 weeks for manufacture Immediately available
No rejection reaction Very low probability of rejection when using young MSC
Limited bulk production 24/7 bulk production possible
High number of collection centres Few collection centres sufficient
1 product/patient 1 product for multiple patients


BioPlanta GmbH
Fürstenweg 8
D-04668 Grimma